Sanofi and GSK in advanced discussions with European Union to supply up to 300 million doses of COVID-19 vaccine

Sanofi and GSK selected for Operation Warp Speed to supply United States government with 100 million doses of COVID-19 vaccine

Nirsevimab reduced respiratory syncytial virus infections requiring medical care in healthy premature infants in Phase 2b trial

Online availability of Sanofi’s half-year financial report for 2020

Sanofi H1 2020 business EPS(1) growth of 9.2%(2) driven by transformation

Sanofi and GSK agree with the UK government to supply up to 60 million doses of COVID-19 vaccine

Availability of the Pre-quarterly Results Communication

Sanofi and Regeneron provide update on Kevzara® (sarilumab) Phase 3 U.S. trial in COVID-19 patients

Sanofi’s virtual R&D Day event to highlight capabilities, platforms, and expertise in disease pathways to deliver potentially transformative treatments to patients

Sanofi and Translate Bio expand collaboration to develop mRNA vaccines across all infectious disease areas